References
- Sánchez-Carbayo M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol.33, 347–361 (2012).
- Chan MW, Chan LW, Tang NL et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res.8, 464–470 (2002).
- Friedrich MG, Weisenberger DJ, Cheng JC et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res.10, 7457–7465 (2004).
- Sathyanarayana UG, Maruyama R, Padar A et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res.64, 1425–1430 (2004).
- Hoque MO, Begum S, Topaloglu O et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst.98, 996–1004 (2006).
- Yates DR, Rehman I, Meuth M et al. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene25, 1984–1988 (2006).
- Urakami S, Shiina H, Enokida H et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin. Cancer Res.12, 2109–2116 (2006).
- Yu J, Zhu T, Wang Z et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin. Cancer Res.13, 7296–7304 (2007).
- Hoque MO, Begum S, Brait M et al. Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J. Urol.179, 743–747 (2008).
- Cebrian V, Alvarez M, Aleman A et al. Discovery of myopodin methylation in bladder cancer. J. Pathol.216, 111–119 (2008).
- Aleman A, Cebrian V, Alvarez M et al. Identification of PMF1 methylation in association with bladder cancer progression. Clin. Cancer Res.14, 8236–8243 (2008).
- Costa VL, Henrique R, Danielsen SA et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin. Cancer Res.16, 5842–5851 (2010).
- Reinert T, Modin C, Castano FM et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin. Cancer Res.17, 5582–5592 (2011).
- Serizawa RR, Ralfkiaer U, Dahl C et al. Custom-designed MLPA using multiple short synthetic probes: application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer. J. Mol. Diagn.12, 402–408 (2010).
- Cabello MJ, Grau L, Franco N et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J. Mol. Diagn.13, 29–40 (2011).
- Zuiverloon TC, Beukers W, van der Keur KA et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int.109(6), 941–948 (2012).
- Hanke M, Hoefig K, Merz H et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol.28, 655–661 (2010).
- Yamada Y, Enokida H, Kojima S et al. miR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci.102, 522–529 (2011).
- Wang G, Chan ES, Kwan BC et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin. Genitourin. Cancer doi:10.1016/j.clgc.2012.01.001 (2012) (Epub ahead of print).
- Puerta-Gil P, García-Baquero R, Jia AY et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and non-invasive diagnostic biomarkers for bladder cancer. Am. J. Pathol.180(5), 1808–1815 (2012).